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The melanoma cell adhesion molecule defines mesenchymal stromal cells in the human bone marrow that regenerate bone
and establish a hematopoietic microenvironment in vivo. The role of the melanoma cell adhesion molecule in primary human
mesenchymal stromal cells and the maintenance of hematopoietic stem and progenitor cells during ex vivo culture has not yet
been demonstrated. We applied RNA interference or ectopic overexpression of the melanoma cell adhesion molecule in human
mesenchymal stromal cells to evaluate the effect of the melanoma cell adhesion molecule on their proliferation and differen-
tiation as well as its influence on co-cultivated hematopoietic stem and progenitor cells. Knockdown and overexpression of
the melanoma cell adhesion molecule affected several characteristics of human mesenchymal stromal cells related to
osteogenic differentiation, proliferation, and migration. Furthermore, knockdown of the melanoma cell adhesion molecule in
human mesenchymal stromal cells stimulated the proliferation of hematopoietic stem and progenitor cells, and strongly
reduced the formation of long-term culture-initiating cells. In contrast, melanoma cell adhesion molecule-overexpressing
human mesenchymal stromal cells provided a supportive microenvironment for hematopoietic stem and progenitor cells.
Expression of the melanoma cell adhesion molecule increased the adhesion of hematopoietic stem and progenitor cells to
human mesenchymal stromal cells and their migration beneath the monolayer of human mesenchymal stromal cells. Our
results demonstrate that the expression of the melanoma cell adhesion molecule in human mesenchymal stromal cells deter-
mines their fate and regulates the maintenance of hematopoietic stem and progenitor cells through direct cell-cell contact. 
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Introduction
Multipotent human mesenchymal stromal cells (hMSC)
support the growth of hematopoietic stem and progenitor
cells (HSPC) during ex vivo co-culture.1-3 hMSC produce vari-
ous growth factors, adhesion molecules, and matrix proteins
contributing to the formation of stem cell niches, thereby
controlling the homing, maintenance, and differentiation of
HSPC.1,4 Well-studied signaling pathways within this niche
include Notch, Wnt, and Hedgehog.5,6 Soluble signaling mole-
cules include cytokines, growth factors, or chemokines (e.g.
stem cell factor (SCF), the FLT3 ligand (FLT3-L), and stromal
derived factor-1 (SDF-1)).7,8 It is believed that direct cell-cell
contact mediated by adhesion molecules is essential for the
maintenance of immature HSPC. Several adhesion molecules
(VCAM-1, ICAM-1, N-cadherin, and NCAM) are known to
be important for niche formation4,6-8 and hematopoiesis.
The melanoma cell adhesion molecule (MCAM/CD146) is
used as a marker for mesenchymal stromal cells. In a xeno-
transplantation model, Sacchetti et al. demonstrated that cul-
ture-expanded MCAM+ bone marrow stromal cells reconsti-
tuted the hematopoietic microenvironment.9 Furthermore,
the expression pattern of MCAM on bone marrow-derived
mesenchymal stromal cells correlated with their in situ local-
ization.10 However, the exact function of MCAM within the
human bone marrow niche is unclear. MCAM is a 113 kDa
glycoprotein that belongs to the immunoglobulin (Ig) super-
family of cell adhesion molecules. It contains an extracellular
domain with five Ig domains (V-V-C2-C2-C2), a transmem-
brane domain, and a cytoplasmic domain with potential
recognition sequences for protein kinases.11 MCAM orthologs
have been identified in mouse, rat, chicken, and zebrafish.12
Human MCAM was originally identified as a marker for
melanoma progression and metastasis. MCAM is further
expressed by the vascular endothelium, smooth muscle cells,
activated T lymphocytes, and bone marrow stromal cells.11
MCAM function has been extensively studied in melanomas
and other types of cancer (prostate cancer and breast cancer),
but the ligand for MCAM has not yet been identified.12-14
This study aimed to clarify the impact of MCAM expres-
sion on the functional properties of hMSC and the mainte-
nance of HSPC in co-culture. Thus, we generated primary
hMSC that stably expressed shRNA against MCAM or that
over-expressed an MCAM coding sequence (CDS) through
lentiviral vector gene transfer. Our findings indicate that
MCAM expression has a pivotal role in hMSC differentiation
and the maintenance of HSPC through direct cell-cell contact. 
Design and Methods
Isolation of hMSC and HSPC
Primary hMSC and HSPC were isolated from healthy donors after
informed consent and the approval of the local ethics committee.
Primary hMSC were isolated from bone marrow aspirates, as
described previously.15 CD34+ HSPC were purified from either
mobilized peripheral blood or umbilical cord blood using CD34
antibody-conjugated magnetic beads (Miltenyi Biotec, Bergisch
Gladbach, Germany), according to the manufacturer’s instruc-
tions. The purity of hMSC and HSPC cells was evaluated by flow
cytometry (hMSC: CD45−, CD34−, CD73+, CD90+, CD105+,
CD166+; HSPC: CD45+, CD34+, CD133+, CD38–/dim). hMSCs were
cultured in DMEM GlutaMax (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FCS; Biochrom,
Cambridge, UK). All experiments were performed with hMSC
that were passaged only once to avoid any variations due to the
aging of cells. Isolated HSPCs were cultured in corresponding
media.
Lentiviral vectors, virus vector production, and hMSC
transduction 
Plasmid pLKO.1 vectors encoding shRNAs that targeted human
MCAM (KD1 and KD2) were obtained from OpenBiosystems
(Huntsville, AL, USA). Control pLKO.1 vectors (empty vector con-
trol or vector with shRNA targeting eGFP) were obtained from
Sigma-Aldrich (Taufkirchen, Germany). 
The MCAM coding sequence was amplified from a cDNA
library and directionally cloned into the lentiviral vector
pRRL.SIN.cPPT.SFFV.GFP.WPRE16,17 (kindly provided by
Christopher Baum, Hannover, Germany) fused with an IRES-GFP
sequence (MCAM-GFP) using XhoI/BamHI restriction sites. To
produce lentiviral vector particles, HEK293T cells were transfected
with lentiviral vectors in combination with the packaging plas-
mids psPAX and pVSVg using PEI.18 Lentivirus-vector containing
media were collected 48 h after transfection. Primary hMSC were
infected three times with lentiviral vector particles (0.5 x viral
supernatant) in the presence of 1 mg mL−1 protamine every 12 h.
Assessment of cell differentiation, proliferation, 
b-galactosidase staining and migration of transduced
hMSC
Twelve hours after seeding the transduced hMSC, the medium
was replaced with differentiation medium. Osteogenic differenti-
ation medium was supplemented with 10 mM b-glycerophos-
phate, 5 mM dexamethasone, and 200 mM ascorbic acid (Sigma-
Aldrich). Mineralization was analyzed with von Kossa staining ten
days after differentiation. In brief, cells were washed once with
phosphate-buffered saline (PBS), fixed with 3.7% formaldehyde,
washed, stained with 1% AgNO3, and developed using 0.1%
pyrogallol. Alkaline phosphatase activity was measured in cell
extracts using the pNPP Liquid Substrate System (Sigma-Aldrich).
The adipogenic differentiation medium contained 50 mM dexam-
ethasone, 500 mM 3-isobutyl-1-methylxanthine, 1 mg mL−1 insulin,
and 100 mM indomethacin (Sigma-Aldrich). Adipocytes were
quantified after 14 days using Oil Red staining. In brief, cells were
washed with PBS, fixed with 4% paraformaldehyde, washed, and
stained with Oil Red solution for 15 min at room temperature.
Excess stain was removed using two washes with 60% ethanol.
Adipocytes were visualized using a microscope (Zeiss Axiovert
400M; 100x magnification). Cell proliferation was measured using
a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT; Roche, Mannheim, Germany) assay. In brief, 1000 cells/96-
wells were seeded in five replicates and grown for 96 h. MTT was
added to prepare a final concentration of 0.5 mg mL−1. Formazan
crystals were solubilized overnight and the absorbance was meas-
ured at 570 nm. For the EdU (5-ethynyl-2’-deoxyuridine) incorpo-
ration assay (Invitrogen), 1.5x105 cells were seeded in a T25 flask.
Twelve hours after seeding, EdU was added to the cell culture
medium to prepare a final concentration of 10 mM. After 24 h incu-
bation, cells were harvested and analyzed by flow cytometry,
according to the manufacturer’s instructions. Cells without EdU
incorporation were used as negative control. Cell cycle analysis
was measured simultaneously with EdU incorporation by 7-AAD-
staining. To detect senescent cells, 1x104 cells/24-well were seeded
in duplicate for b-galactosidase staining (Cell Signaling
Technology, Boston, MA, USA). Twenty-four hours after seeding,
cells were subjected to a b-galactosidase assay, according to the
manufacturer’s instructions.
In vitro wounding assays were performed using 6-well plates to
assess cell migration. Confluent hMSC monolayer were wounded
with sterile 1000 mL pipette tips, washed twice with PBS to
remove non-adherent cells, and incubated further in complete
growth medium. Wounds were imaged at 0 h and after 20 h using
phase-contrast microscopy. To mimic constitutive RhoA activa-
tion, 10 mM Nocodazole (Sigma Aldrich) was added to cell culture
for 20 h. Cell migration was quantified using the ImageJ program
(NIH, Bethesda, MD, USA).
Statistical analysis
Statistical analysis was performed using paired Student t-tests.
The Cochran-Mantel-Haenszel test was used to assess qualitative
differences in the formation of secondary colonies. Statistical sig-
nificance was tested at *P<0.05, **P<0.01 and ***P<0.001. All
results were expressed as mean±standard error of the mean (SEM)
for at least 3 donors.
Results
Generation and characterization of MCAM knockdown
or MCAM overexpression in primary hMSC
To analyze the role of MCAM within the bone marrow
niche in vitro, we used lentiviral vector gene transfer to
establish primary hMSC that stably expressed shRNAs
against MCAM or that overexpressed MCAM CDS (Online
Supplementary Figure S1). Protein and mRNA levels were
analyzed to validate MCAM knockdown or overexpres-
sion. As shown in Online Supplementary Figure S1A,
immunoblotting of whole cell lysates indicated a reduction
in the MCAM protein level to 36% or 52% for two MCAM
specific shRNAs, MCAM-KD1 and MCAM-KD2, respec-
tively, compared with cells expressing control shRNA
against eGFP or the empty pLKO.1 vector. Upon MCAM
overexpression, the relative protein level was up-regulated
10.5-fold. Flow cytometric analysis of MCAM surface
expression confirmed these results (Online Supplementary
Figure S1B and C). Compared with pLKO.1 control, the
average downregulation of MCAM expression after
MCAM KD was 65% according to the mean fluorescence
intensity (MFI). MCAM overexpression showed an average
8.2-fold upregulation in comparison to control (Online
Supplementary Figure S1E). MCAM mRNA levels were sim-
ilarly reduced to 24% and 34% for MCAM-KD1 and
MCAM-KD2, respectively, compared to control. In con-
trast, MCAM overexpression strongly increased the mRNA
level (130-fold; Online Supplementary Figure S1D). Because of
the stronger knockdown, MCAM-KD1 was used in further
experiments where it is referred to as MCAM-KD. The
expression of typical hMSC surface markers (CD73, CD90,
CD105, CD166) was unchanged after knockdown or over-
expression of MCAM (data not shown).
Subsequently, we characterized the effects of MCAM
knockdown and overexpression on the differentiation
potential of osteogenic and adipogenic lineages (Figure 1A-
C). von Kossa staining and ALP activity measurements
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showed that MCAM knockdown in hMSC resulted in a
significantly reduced potential of hMSC in differentiating
into the osteogenic lineage (ALP: MCAM-KD 56.8±30.3
mU mg−1 vs. pLKO.1 175.8±58.3 mU mg−1; P<0.05; Figure
1A and B). Interestingly, the potential for adipogenic differ-
entiation was also significantly decreased by MCAM
knockdown compared with the control cells (MCAM-KD
1.6±0.45% vs. pLKO.1 5.7±1.4% adipogenic differentia-
tion; P<0.05; Figure 1A and C). In contrast, MCAM-over-
expressing hMSC exhibited a significantly increased
osteogenic differentiation compared with their respective
control cells (ALP: MCAM-GFP 344.8±118.9 mU mg−1 vs.
IRES-GFP 272.1±106.4 mU mg−1; P<0.05; Figure 1A and
B). However, adipogenic differentiation was not affected
by MCAM overexpression (MCAM-GFP 6.8±2.7% vs.
IRES-GFP 7.3±2.65% adipogenic differentiation; Figure
1A and C). 
We further examined the proliferative behavior of
hMSC after MCAM knockdown or overexpression using
an MTT assay (Figure 1D) and by EdU incorporation
(Figure 1E). MCAM knockdown resulted in a significant
2.3-fold decrease in metabolic activity and a 5.3-fold lower
DNA synthesis rate compared with the pLKO.1-control.
In contrast, MCAM-overexpressing hMSC showed an
enhanced metabolic activity (1.4-fold) and an increased
DNA synthesis rate (1.4-fold) compared with the IRES-
GFP-control-transduced hMSC.
To analyze the impact of the varying proliferative capac-
ity of transduced hMSC on the support of HSPC during
co-culture we seeded equal numbers of hMSC as conflu-
ent layer. Counting hMSC numbers five days and four
weeks after plating, no significant differences in cell num-
bers were observed between MCAM-KD and MCAM-
GFP transduced hMSC, suggesting that contact inhibition
prevented overgrowth of MCAM-GFP hMSC (data not
shown).
Cell cycle analysis indicated cell cycle arrest during G1/S
phase after MCAM knockdown (data not shown).
Furthermore, p21 expression was up-regulated 2.9-fold in
MCAM-KD hMSC compared with pLKO.1-control cells,
whereas the p21 mRNA level was down-regulated 2.1-
fold in MCAM-overexpressing hMSC (Figure 1F).
Furthermore, the expression of CDK2 and Cyclin E (both
promote G1/S phase cell cycle progression) were
decreased upon MCAM knockdown. Also, the Rb
(Retinoblastoma) protein was almost completely dephos-
phorylated upon MCAM knockdown compared with
pLKO.1-control cells (Figure 1G). To confirm the impaired
proliferation capacity upon MCAM knockdown, PCNA
(proliferating cell nuclear antigen) was evaluated showing
a decreased PCNA expression. In contrast, MCAM over-
expressing hMSC exhibited an increased CDK2, Cyclin E
and PCNA expression as well as an elevated phosphoryla-
tion of the Rb protein. The p53 expression level was not
altered in hMSC with both MCAM-KD and MCAM over-
expression (data not shown). Cells were stained to deter-
mine b-galactosidase accumulation, which is known to be
a senescence marker, to test whether MCAM knockdown
cells assumed a senescent-like phenotype.19 hMSC with
MCAM knockdown were highly positive for senescence
associated (SA)-b-galactosidase staining (data not shown). 
MCAM expression influences the cell motility in
melanoma and endothelial cells,20,21 so we further analyzed
the migratory potential of hMSC after MCAM knock-
down or overexpression. As shown in Figure 1H, MCAM
knockdown led to impaired migration, whereas MCAM-
overexpressing hMSC exhibited enhanced migration dur-
ing in vitro wounding assays.
MCAM expression by hMSC maintains 
CD34+CD133+ HSPC
We used an MSC–HSPC co-culture system to determine
whether MCAM expression on hMSC supports HSPC
during ex vivo expansion.22 Freshly isolated HSPC from G-
CSF mobilized leukapheresis products were co-cultured
on established MCAM-KD or MCAM-overexpressing
hMSC monolayer for five days. To characterize the HSPC
in more detail, the expression levels of CD34 and CD133
(characteristics of immature HSPC) as well as markers for
early myeloid (CD13, CD33) and lymphoid (CD10,
CD56) lineages were analyzed by flow cytometry (Figure
2). As shown in Figure 2A, co-culture of CD45+ HSPC on
an hMSC monolayer with MCAM knockdown resulted in
a significant decrease in CD34 expression. A significant
reduction in the proportion of CD45+CD34+CD133+ cells
was also observed. In contrast, after five days of ex vivo co-
culture with MCAM-overexpressing hMSC, HSPC main-
tained a significantly higher CD34 expression and a higher
proportion of CD34+CD133+ cells compared with co-cul-
tures including IRES-GFP-control vector transduced hMSC
(Figure 2B; Table 1). In line with these results, the percent-
age of more mature hematopoietic cell subsets (myeloid:
CD34–CD33+ and CD34–CD13+; lymphoid: CD34–CD10+
and CD34–CD56+) was higher after five days of ex vivo co-
culture with MCAM knockdown hMSC compared with
pLKO.1-control (Figure 2C; Table 1), whereas co-culture
with MCAM-overexpressing hMSC showed significantly
reduced proportions of more mature cell subsets (Figure
2D; Table 1). When using non-contact conditions, we
found no difference in the CD34 expression on HSPC or
in the proportion of CD34+CD133+ HSPC with MCAM-
KD or MCAM-overexpressing hMSC compared with
their respective controls (data not shown). These data sug-
gest that the maintenance of HSPC was mediated by
direct cell-cell contact. HSPC co-cultured on hMSC with
MCAM knockdown lost their immature phenotypes more
rapidly than HSPC cultured on pLKO.1-control transduced
hMSC. Therefore, we further tested whether MCAM
expression by hMSC also affected the proliferation of
HSPC. Thus, the cell division history of HSPC was tracked
during co-culture using CFSE staining. As shown in Figure
2E, HSPC maintained for five days on MCAM knock-
down hMSC demonstrated a significantly higher prolifer-
ation rate than HSPC maintained on pLKO.1-control
transduced hMSC (cell division peak: MCAM-KD 7 vs.
pLKO.1 6). The increased cell proliferation was also asso-
ciated with a simultaneous loss of CD34 expression. In
contrast, MCAM overexpression resulted in the opposite
effect (cell division peak: MCAM-GFP 5 vs. IRES-GFP 6;
Figure 2F).
To determine whether HSPC displayed different behav-
ior of adhesion to MCAM-KD or MCAM-overexpressing
hMSC, the number of attached cells was counted 24 h
after seeding (Online Supplementary Figure S2). Co-culture
with MCAM-KD hMSC led to a reduced number of
adherent HSPC on the monolayer compared with the
pLKO.1-control transduced monolayer (5.2±1.6x104 vs.
7.6±2x104 cells mL−1; P<0.05), whereas MCAM-overex-
pressing hMSC provided greater support for HSPC adhe-
sion to the hMSC monolayer compared with the control
MCAM in hMSC effects maintenance of HSPC
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Figure 1. MCAM expression in hMSC enhances osteogenic differentiation, cell proliferation, and migration. (A) MCAM knockdown or overexpressing
hMSC were cultured in osteogenic or adipogenic differentiation medium for 10 and 14 days, respectively. Osteogenic differentiation was monitored
by von Kossa staining (Zeiss, Axiovert 400M; magnification 200x) and adipogenic differentiation by Oil Red staining (magnification 100x). (B)
Osteogenic differentiation was quantified based on ALP activity 10 days after induction. Mean±SEM of at least 3 donors is shown (*P<0.05; paired
Student’s t-test). (C) Adipogenic differentiation was quantified based on Oil Red positive cells after 14 days of differentiation using in-house quan-
tification software. Mean±SEM of at least 3 donors is shown (*P<0.05; paired Student’s t-test). Cell proliferation of MCAM knockdown or MCAM-
overexpressing hMSC was assessed by MTT assay and EdU incorporation. (D) In the MTT assay, hMSC expressing MCAM shRNA or MCAM CDS
were grown for 96 h. Proliferation was normalized relative to the respective control cells (pLKO.1 vs. MCAM-KD; IRES-GFP vs. MCAM-GFP; paired
Student’s t-test). (E) In the EdU incorporation assay, cells were labeled with 10 mM EdU for 24 h and analyzed by flow cytometry. Mean±SEM for
at least 3 donors is shown (*P<0.05; **P<0.01; paired Student’s t-test). (F) Quantitative RT-PCR of the p21 mRNA levels. Results are normalized
relative to the respective control cells (pLKO.1 vs. MCAM-KD; IRES-GFP vs.MCAM-GFP). Mean±SEM for at least 3 donors is shown (*P<0.05; paired
Student’s t-test). (G) Expression of cell-cycle regulators CDK2, Cyclin E and PCNA, as well as phosphorylation status of retinoblastoma (Rb) were
assessed by immunoblotting in whole cell lysates of MCAM knockdown or MCAM-overexpressing hMSC and respective control cells (pLKO.1; IRES-
GFP). Gapdh expression was used as loading control. (H) Migration of hMSC expressing MCAM-targeting shRNA, MCAM CDS, or the respective
control vectors (pLKO.1 vs. MCAM-KD; IRES-GFP vs. MCAM-GFP) were subjected to in vitro wounding assays. Wounds were quantified after 20 h
using ImageJ software. Mean±SEM of 5 donors is shown (*P<0.05; paired Student’s t-test).
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(11.9±3.8 x 104 vs. 9.3±3.4x104 cells mL−1; P<0.05). In that
context, we analyzed the surface expression of CD29 (b1-
integrin) and found CD29 to be up-regulated upon
MCAM knockdown (1.3-fold) and down-regulated upon
MCAM overexpression (1.9-fold; Online Supplementary
Figure S2B). However, the adhesion behavior of HSPC to
MCAM-KD or MCAM-GFP hMSC does not depend on
CD29 expression. Blocking of CD29 and another integrin,
CD49e (a5-integrin) using neutralizing antibodies did not
affect the adhesion of HSPC to MCAM-KD or MCAM-
GFP hMSC (data not shown). In agreement with the study
by Guezguez et al.,14 MCAM better supported the migra-
tion of HSPC beneath the hMSC monolayer compared
with the control transduced cells (MCAM-GFP 29.2±5.1%
vs. IRES-GFP 22.5±4.1% P<0.05; Online Supplementary
Figure S2B), whereas MCAM knockdown hMSC showed
MCAM in hMSC effects maintenance of HSPC
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Figure 2. MCAM expression
on hMSC supports
CD34+CD133+ HSPC during
ex vivo co-culture. (A) HSPC
from leukapheresis were
co-cultured on MCAM
knockdown or (B) MCAM-
overexpressing hMSC
monolayer for five days and
analyzed by flow cytometry
to determine the mean flu-
orescence intensity (MFI) of
CD34 expression in CD45+
HSPC and the proportion of
CD45+CD34+CD133+ HSPC.
Graphs show the
mean±SEM for at least 5
donors (*P<0.05;
**P<0.01; paired Student’s
t-test). (C) HSPC from
leukapheresis were co-cul-
tured on MCAM knockdown
or (D) MCAM-overexpress-
ing hMSC as described in
(A) and the proportion of
C D 4 5 + C D 3 4 – C D 3 3 + ,
C D 4 5 + C D 3 4 – C D 1 3 + ,
CD45+CD34–CD10+ and
CD45+CD34–CD56+ HSPC
was analyzed by flow
cytometry. Graphs show
the mean±SEM of 4 donors
(*P<0.05; paired Student’s
t-test). (E) Representative
FACS plots of CFSE-tracked
HSPC co-cultured on MCAM
knockdown or (F) MCAM
overexpressing hMSC and
co-stained for CD34.
Graphs show the percent-
age of total cells in each
cell division cycle calculat-
ed as mean±SEM for at
least 3 donors (*P<0.05,
**P<0.01; paired Student’s
t-test).
less support for transmigration of HSPC beneath the
hMSC monolayer (18.1±2.9% vs. 23.4±4.2%, P<0.05).
SDF-1 expression and secretion were analyzed to deter-
mine whether SDF-1 contributed to the observed pheno-
type. However, we observed no significant differences in
SDF-1 expression or secretion after MCAM knockdown or
overexpression (data not shown). 
MCAM supports the maintenance of long-term 
culture-initiating cells
Long-term culture-initiating cell (LTC-IC) assays were
performed to further understand the role of MCAM
expression on hMSC for the maintenance of HSPC (Figure
3). HSPC from umbilical cord blood were cultured on
MCAM knockdown or MCAM-overexpressing hMSC
monolayer for four weeks. The total number of cobble-
stone-area forming cells (CAFC) was decreased 5.4-fold on
MCAM knockdown monolayer compared with pLKO.1-
control transduced monolayer (6.6±1.5 vs. 35.5±6.3;
P<0.001; Figure 3A). MCAM-overexpressing hMSC pro-
moted a 1.7-fold increase in CAFCs compared with
CAFCs on the IRES-GFP-control transduced monolayer
(63.8±10.2 vs. 36.6±4.9; P<0.01; Figure 3A). After four
weeks of co-culture, we transferred CAFC-derived HSPC
into semi-solid medium to quantify their capacity in sec-
ondary colony-forming cell assays (CFU; Figure 3B). We
found a 2.1-fold lower CFU frequency (1.8%±0.5% vs.
3.8%±1.3%; P<0.05) in co-cultures with MCAM knock-
down monolayer and a 1.6-fold higher CFU frequency
(5.7%±1.5% vs. 3.8%±1.4%; P<0.01) after co-culture with
MCAM-overexpressing hMSC compared to control.
There were no significant qualitative differences in the for-
mation of granulocytic (CFU-G), monocytic (CFU-M) or
erythrocytic (BFU-E) lineages (Figure 3C).
MCAM knockdown induces RhoA activation
Since MCAM knockdown hMSC showed reduced
migratory potential (Figure 1H) and an altered morpholo-
gy associated with cell enlargement and stress fiber forma-
tion (Online Supplementary Figure S4B), we tested whether
this could be mediated via the small GTPase RhoA.
Therefore, we performed pull-down experiments to iso-
late active GTP-bound RhoA. As shown in Online
Supplementary Figure S4A, MCAM knockdown hMSC
exhibited a higher level of active RhoA compared to
pLKO.1-control hMSC (1.47-fold). MCAM-overexpress-
ing hMSC showed a decrease in the level of active RhoA
compared to IRES-GFP-control hMSC (0.65-fold) indicat-
ing that MCAM expression modulates RhoA activity. To
test whether we could pharmacologically mimic the mor-
phological and migratory phenotype of MCAM knock-
down in hMSC, transduced hMSC were treated with 10
mM Nocodazole, a known RhoA activator.23 As shown in
Online Supplementary Figure S4B, Nocodazole treatment of
hMSC resulted in stress formation and impaired migration
(Online Supplementary Figure S4C) in MCAM KD hMSC,
MCAM overexpressing hMSC as well as in control hMSC.
These data indicate that MCAM expression in hMSC
modulates RhoA activity.
Discussion
During the last two decades, the characterization of the
microenvironment regulating the fate of hematopoietic
stem and progenitor cells (HSPC) has been an area of
active research. Recent reports show that the cellular com-
position of the stem cell niche is more complex24 than ini-
tially described.25 Several groups have identified subsets of
MSC populations as potential organizers of the
hematopoietic microenvironment.2,19,26-29 Sacchetti et al.
found a population of self-renewing CD45−/MCAM+
perivascular osteoprogenitors in the adult human bone
marrow.1 Furthermore, Tormin et al. recently reported that
MCAM expression correlated with its in situ localization.10
Both reports suggest that MCAM+ cells are an important
component of the niche microenvironment. However, the
functional relevance of MCAM in primary human MSC
has not yet been described.
Recent studies of human term placenta-derived MSC
demonstrated that MCAM expression correlated with the
osteogenic differentiation potential of MSC.30 Consistent
with these data, we found that MCAM expression strong-
ly affected the osteogenic differentiation potential of
hMSC (Figure 1A and B). Our data suggest that MCAM
knockdown also affected the potential for differentiating
into an adipogenic lineage (Figure 1A and C). This sug-
gests a global change in the intracellular signaling path-
ways relevant to differentiation.31 In addition to the effect
of MCAM on the differentiation potential of MSC, several
lines of evidence suggest that MCAM expression also
influences proliferation potential.25-27 This was demon-
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Table 1. Proportion of lineage specific subsets in the different compartments
(non-adherent, phase-bright, phase-dim) after five days of co-culture with
MCAM-KD or MCAM-GFP hMSC. pLKO.1 (for MCAM-KD) and IRES-GFP (for
MCAM-GFP) transduced hMSC served as controls. MCAM overexpression main-
tained CD34 expression and the proportion of CD34+CD133+ HSPC compared
with MCAM-KD in hMSC. MCAM-KD in hMSC resulted in an increased commit-
ment into myeloid and lymphoid lineage. 
Lineage Compartment Marker MCAM-KD MCAM-GFP
(n-fold to (n-fold to
control) control)
HSPC
Non-adherent CD34+ 0.8±0.06 1.2±0.13
CD34+CD133+ 0.6±0.04 1.3±0.15  
Phase-bright CD34+ 0.7±0.04 1.3±0.04
CD34+CD133+ 0.7±0.03 1.4±0.15
Phase-dim CD34+ 0.8±0.05 1.2±0.05
CD34+D133+ 0.5±0.07 1.3±0.10
Lymphoid differentiation
Non-adherent CD34–CD10+ 2.1±0.34 0.8±0.06
CD34–CD56+ 1.9±0.26 0.8±0.10
Phase-bright CD34–CD10+ 2.1±0.08 0.7±0.08
CD34–CD56+ 2.4±0.53 0.7±0.09
Phase-dim CD34–CD10+ 1.6±0.17 0.8±0.08
CD34–CD56+ 1.4±0.13 0.7±0.05
Myeloid differentiation
Non-adherent CD34–CD13+ 1.3±0.04 0.9 0.06
CD34–CD33+ 1.3±0.05 0.9±0.03
Phase-bright CD34–CD13+ 1.6±0.18 0.8±0.07
CD34–CD33+ 1.5±0.15 0.8±0.03
Phase-dim CD34–CD13+ 1.6±0.08 0.7±0.07
CD34–CD33+ 1.4±0.14 0.8±0.07
HSC compartment: CD34+, CD34+CD133+; lymphoid lineage: CD34-CD10+, CD34–CD56+; myeloid lin-
eage: CD34–, CD13+, CD34-CD33+. Data show proportions of depicted cell populations divided by
the values obtained with corresponding control cells of at least 4 donors as mean ± SEM.
strated using MCAM+ hMSC that were initially derived
from clonogenic colony-forming fibroblasts (CFU-F).9 We
confirmed that MCAM knockdown impaired the prolifer-
ation of hMSC (Figure 1D and E). This functional observa-
tion was associated with G1/S-phase cell cycle arrest
mediated by the upregulation of p21 expression, the
reduced expression of CDK2 and Cyclin E (Figure 1F and
G) and the adoption of a senescent-like phenotype (data
not shown). 
MCAM seems to be relevant to the cell motility of
melanoma and endothelial cells.20,21,32 In agreement with
these findings, we demonstrate that MCAM expression
also affects the migration of hMSC (Figure 1H). Luo et al.
suggested a possible molecular mechanism whereby
MCAM may be involved in cytoskeleton remodeling and
cell migration. These authors demonstrated an association
between MCAM and ERM proteins that further induced
RhoA activation.21 Other groups showed that inhibition of
RhoA induces cell migration.33 We found elevated RhoA
activity in hMSC upon MCAM knockdown with induced
stress fiber formation and reduced migration (Online
Supplementary Figure S4).
It is well established that mesenchymal stromal cells
and soluble factors support the maintenance and prolifer-
ation of HSPC through different adhesion mole-
cules.1,5,8,22,34-36 Several groups have described the involve-
ment of adhesion proteins such as N-cadherin, CD44,
CD29, NCAM, or Notch, in mediating a direct interaction
with the cellular microenvironment that enhances HSPC
self-renewal.1,4,37-41 We found that MCAM overexpression
in hMSC led to reduced CD29 expression. In line with our
findings, Walenda et al. reported that siRNA-mediated
CD29 knockdown in hMSC resulted in enhanced num-
bers of more primitive HSPC after co-culture with these
hMSC.42 Furthermore, we demonstrate that MCAM
knockdown resulted in an increased CD29 expression on
hMSC, and an enhanced proliferation of HSPC associated
with a loss of the more immature HSPC (Figure 2, Table
1). Long-term co-culture of HSPC with MCAM KD hMSC
demonstrated a reduced capacity to facilitate the growth
of cobblestone-forming HSPC, whereas a significantly
higher number of CAFC (Figure 3A) and CFU frequency
(Figure 3B) was found in co-culture with hMSC overex-
pressing MCAM. MCAM overexpression on hMSC main-
tained the immature cell fraction of HSPC that has a slow-
er proliferation rate and is characterized by CD34 and
CD133 expression (Figure 2). As we showed previously,
the CD34+CD133+ cell fraction constitutes the HSPC sub-
set with the highest marrow reconstitution potential in an
NOD/SCID xenotransplantation model.41
Here we show that MCAM has a crucial role in regulat-
ing the proliferation and maintenance of HSPC during ex
vivo co-culture (Figures 2 and 3 and Online Supplementary
Figure S2). MCAM knockdown resulted in a severe impair-
ment of the supportive function of hMSC for HSPC,
whereas MCAM overexpression supported the mainte-
nance of HSPC independent of MSC fate.
In contrast to our results, Sharma and co-workers
demonstrated an increased support of HSPC by placenta-
derived MCAM negative hMSC.43 These placenta-derived
hMSC are initially MCAM positive. After culture in a 3-
dimensional hydrogel-based matrix, which constitutes
hypoxic conditions, MCAM expression is lost.
Concordantly, Tormin et al. demonstrated that MCAM is
down-regulated under hypoxic conditions.10 Furthermore,
it was shown by others and our group that oxygen tension
causes selective modification of hematopoietic cell and
mesenchymal stromal cell interactions in co-culture sys-
tems as well as influence HSPC metabolism.44-46 Thus, the
observed differences between Sharma et al. and our data
in HSPC supporting capacity of hMSC are likely due to
the different culture conditions used. Further studies are
required to clarify the influence of hypoxia in our model
system. Altogether these findings provide further evidence
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Figure 3. MCAM expression is important for the long-term mainte-
nance of HSPC. (A) HSPC derived from umbilical cord blood were cul-
tured on hMSC that stably expressed MCAM shRNA or that over-
expressed MCAM in long-term initiating cell assays (LTC-IC). Colony-
area forming cells (CAFC) were counted after four weeks. Mean±SEM
for 4 independent hMSC and HSPC donors is shown (**P<0.01;
***P<0.001; paired Student’s t-test). (B) Clonal growth of CAFC
derived HSPCs after four weeks of co-culture on MCAM knockdown or
MCAM-overexpressing hMSC monolayer was analyzed in a secondary
colony-forming cell assay (CFU) for an additional 14 days. The frequen-
cy of CFUs was determined as the total number of colonies relative to
the number of CD45+ cells. Mean±SEM for 4 donors is shown
(*P<0.05; **P<0.01; paired Student’s t-test). (C) Proportion of ery-
throid, granulocytic, or monocytic lineages in the secondary CFU-assay
(Cochran-Mantel-Haenszel test). Mean±SEM for 4 donors is shown.
BFU-E: burst-forming unit-erythroid: CFU-G: colony-forming unit-granu-
locyte; CFU-M: colony-forming unit-macrophage; CFU-GM: colony-form-
ing unit-granulocyte macrophage.
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for the importance of MCAM in supporting HSPC.
Furthermore, previous reports have shown that MCAM is
down-regulated in MSC after several passages as well as
during aging and differentiation.19,47
Interestingly, MCAM overexpression in hMSC
enhanced the adhesion of HSPC to MSC and it further
supported the migration of HSPC (Online Supplementary
Figure S2A and B). Previous reports show that monocyte
transendothelial migration involves a heterophilic interac-
tion between MCAM on endothelial cells and an uniden-
tified counterpart on monocytes.12 The current study also
suggests that MCAM acts through a direct cell-cell interac-
tion (Online Supplementary Figure S2A). However, HSPC do
not express MCAM (Online Supplementary Figure S5), so
the putative interaction partner of MCAM on HSPC
remains elusive. Instead of direct receptor interactions,
functional changes after MCAM expression may also
account for the observed maintenance of HSPC in co-cul-
ture with hMSC. Because the SDF-1/CXCR4 axis has a
key role in the homing and mobilization of HSPC, as well
as having a positive impact on the maintenance of HSPC,
we tested whether SDF-1 is regulated upon MCAM
expression.48-50 However, we observed no effect of MCAM
on SDF-1 expression or secretion by hMSC (data not
shown). The clinical relevance of our findings is that the
functional properties of hMSC are clearly related to
MCAM expression. Tripodo et al. demonstrated an
involvement of MCAM+ osteoprogenitors in the advanced
stages of myelofibrosis.51 Furthermore, MCAM has an
aberrant expression on several tumor cell types52,53 Thus,
MCAM may act as a binding partner for circulating tumor
cells that have been shown to hijack the bone marrow
microenvironment. Therefore, interfering with the action
of MCAM on MSC, or other skeletal progenitor cells and
tumor cells may be an option for reducing the homing of
tumor cells to the bone marrow and their subsequent
metastatic spread.
We showed that MCAM expression in hMSC supports
the growth of hematopoietic progenitors. Further studies
will be required to unravel the intracellular consequences
in hMSC upon MCAM knockdown or overexpression as
well as to establish the in vivo relevance of MCAM expres-
sion for the maintenance of hematopoietic stem cells.
Furthermore, studies should analyze whether MCAM-
overexpressing hMSC are suitable to expand HSPC from
cord blood products to facilitate better engraftment after
allogeneic transplantation, particularly in adult patients
where the quantity of HSPC available in single cord blood
units might be a limiting factor.
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